Kiora Pharmaceuticals’ (KPRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

Kiora Pharmaceuticals Trading Down 3.1 %

Shares of NASDAQ:KPRX opened at $3.62 on Tuesday. The firm’s 50 day moving average price is $3.53 and its 200-day moving average price is $4.29. Kiora Pharmaceuticals has a twelve month low of $3.00 and a twelve month high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, analysts predict that Kiora Pharmaceuticals will post 1.17 EPS for the current fiscal year.

Institutional Trading of Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for approximately 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.